Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : clinical outcomes in real-world patients from the DANBIO registry ', RMD Open, vol. 8, no. 2, e002560 . https://doi.org/10.1136/rmdopen-2022-002560 Nabi, H, Hetland, M L, Loft, A G, Hendricks, O, Jensen, D, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Grydehøj, J, Raun, J, Ahmed, R, Mehnert, F, Krogh, N S & Glintborg, B 2022, ' INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: CLINICAL OUTCOMES IN REAL-WORLD PATIENTS FROM THE DANBIO REGISTRY ', Annals of the Rheumatic Diseases, vol. 81, no. Suppl. 1, OP0065, pp. 45-46 . https://doi.org/10.1136/annrheumdis-2022-eular.2306 Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : Clinical outcomes in real-world patients from the DANBIO registry ', RMD Open, vol. 8, no. 2, 002560 . https://doi.org/10.1136/rmdopen-2022-002560 Nabi, H, Hendricks, O, Jensen, D V, Loft, A G, Pedersen, J K, Just, S A, Danebod, K, Munk, H L, Kristensen, S, Manilo, N, Colic, A, Linauskas, A, Thygesen, P H, Christensen, L B, Kalisz, M H, Lomborg, N, Chrysidis, S, Raun, J L, Andersen, M, Mehnert, F, Krogh, N S, Hetland, M L & Glintborg, B 2022, ' Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease : Clinical outcomes in real-world patients from the DANBIO registry ', RMD open, vol. 8, no. 2, 002560 . https://doi.org/10.1136/rmdopen-2022-002560
Terslev, L, Ostergaard, M, Georgiadis, S, Brahe, C H, Ellegaard, K, Dohn, U M, Fana, V, Møller, T, Juul, L, Huynh, T K, Krabbe, S, Ornbjerg, L M, Glinatsi, D, Røgind, H, Hansen, A, Nørregaard, J, Jacobsen, S, Jensen, D V, Manilo, N, Asmussen, K, Boesen, M, Rastiemadabadi, Z, Morsel-Carlsen, L, Møller, J M, Krogh, N S & Hetland, M L 2022, ' Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care : characteristics and predictors ', RMD Open, vol. 8, no. 2 . https://doi.org/10.1136/rmdopen-2022-002796
Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702 Glintborg, B, Georgiadis, S, Loft, A G R, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Lange Andersen, B, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J L, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, bind 79, nr. 6 . https://doi.org/10.1136/annrheumdis-2019-216702 Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : An observational nationwide study applying linkage between DANBIO and national registries ', Annals of the rheumatic diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4, e37 . https://doi.org/10.1136/annrheumdis-2018-214952 Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to To switch or not to switch' : The missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4, e37 . https://doi.org/10.1136/annrheumdis-2018-214952 Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4 . https://doi.org/10.1136/annrheumdis-2018-214952
Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L & Hetland, M L 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742 Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L, Hetland, M L & all departments of rheumatology in Denmark 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742